Deoxypodophyllotoxin

Name: Deoxypodophyllotoxin
Brand: MedChemExpress
SKU: HY-N2500
Rating: 4.5 (1 reviews)

Cat. No.: HY-N2500 Purity: 99.87%: FAQs
Data Sheet SDS COA Handling Instructions Technical Support

Deoxypodophyllotoxin (DPT), a derivative of podophyllotoxin, is a lignan with potent antimitotic, anti-inflammatory and antiviral properties isolated from Anthriscus sylvestris. Deoxypodophyllotoxin, targets the microtubule, has a major impact in oncology not only as anti-mitotics but also as potent inhibitors of angiogenesis. Deoxypodophyllotoxin induces cell autophagy and apoptosis. Deoxypodophyllotoxin evokes increase of intracellular Ca²⁺ concentrations in DRG neurons.

For research use only. We do not sell to patients.

Deoxypodophyllotoxin Chemical Structure

CAS No. : 19186-35-7

Size	Stock	Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	In-stock	Estimated Time of Arrival: December 31
Solid
1 mg	In-stock	Estimated Time of Arrival: December 31
5 mg	In-stock	Estimated Time of Arrival: December 31
10 mg	In-stock	Estimated Time of Arrival: December 31
50 mg	Get quote
100 mg	Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

Biological Activity
Purity & Documentation
References
Customer Review

Description

Deoxypodophyllotoxin (DPT), a derivative of podophyllotoxin, is a lignan with potent antimitotic, anti-inflammatory and antiviral properties isolated from Anthriscus sylvestris. Deoxypodophyllotoxin, targets the microtubule, has a major impact in oncology not only as anti-mitotics but also as potent inhibitors of angiogenesis^[1]. Deoxypodophyllotoxin induces cell autophagy and apoptosis^[2]. Deoxypodophyllotoxin evokes increase of intracellular Ca²⁺ concentrations in DRG neurons^[3].

Cellular Effect

Cell Line	Type	Value	Description	References
A549	IC₅₀	0.004 μg/mL Compound: 10	Antiproliferative activity against human A549 cells assessed as inhibition of cell viability by MTT assay Antiproliferative activity against human A549 cells assessed as inhibition of cell viability by MTT assay	[PMID: 32223924]
A549	IC₅₀	0.47 μM Compound: 2, DPT	Cytotoxicity against human A549 cells after 48 hrs by MTT assay Cytotoxicity against human A549 cells after 48 hrs by MTT assay	[PMID: 21733601]
A549	IC₅₀	1.38 μM Compound: 9, DPT	Cytotoxicity against human A549 cells after 48 hrs by MTT assay Cytotoxicity against human A549 cells after 48 hrs by MTT assay	[PMID: 22244588]
A549	IC₅₀	1.38 μM Compound: 8, DPT	Cytotoxicity against human A549 cells assessed as growth inhibition after 48 hrs by MTT assay Cytotoxicity against human A549 cells assessed as growth inhibition after 48 hrs by MTT assay	[PMID: 22041063]
BXPC-3	GI₅₀	0.00044 μg/mL Compound: 1	Growth inhibition of human BxPC3 cells measured after 48 hrs by sulforhodamine B assay Growth inhibition of human BxPC3 cells measured after 48 hrs by sulforhodamine B assay	[PMID: 26938998]
BXPC-3	ED₅₀	0.0029 μg/mL Compound: 2	Anticancer activity against human BxPC3 cells after 48 hrs by SRB assay Anticancer activity against human BxPC3 cells after 48 hrs by SRB assay	[PMID: 14987061]
DU-145	GI₅₀	0.0017 μg/mL Compound: 1	Growth inhibition of human DU145 cells measured after 48 hrs by sulforhodamine B assay Growth inhibition of human DU145 cells measured after 48 hrs by sulforhodamine B assay	[PMID: 26938998]
DU-145	ED₅₀	0.0028 μg/mL Compound: 2	Anticancer activity against human DU145 cells after 48 hrs by SRB assay Anticancer activity against human DU145 cells after 48 hrs by SRB assay	[PMID: 14987061]
GLC4 cell line	IC₅₀	0.008 μM Compound: 23	Cytotoxic effect against GLC4 (human small cell lung carcinoma cell line) using the microculture tetrazolium (MTT) assay based on continuous incubation Cytotoxic effect against GLC4 (human small cell lung carcinoma cell line) using the microculture tetrazolium (MTT) assay based on continuous incubation	[PMID: 7783142]
GLC4 cell line	IC₅₀	0.12 μM Compound: 23	Cytotoxic effect against GLC4 (human small cell lung carcinoma cell line) using the microculture tetrazolium (MTT) assay based on 2 hr incubation Cytotoxic effect against GLC4 (human small cell lung carcinoma cell line) using the microculture tetrazolium (MTT) assay based on 2 hr incubation	[PMID: 7783142]
HCT-116	IC₅₀	14.5 nM Compound: DPT	Antiproliferative activity against human HCT-116 cells measured after 72 hrs by MTT assay Antiproliferative activity against human HCT-116 cells measured after 72 hrs by MTT assay	[PMID: 36471625]
HeLa	IC₅₀	0.0069 μM Compound: 7	Cytotoxicity against human HeLa cells after 72 hrs by MTT assay Cytotoxicity against human HeLa cells after 72 hrs by MTT assay	[PMID: 21570846]
HeLa	IC₅₀	1.98 μM Compound: 8, DPT	Cytotoxicity against human HeLa cells assessed as growth inhibition after 48 hrs by CCK-8 assay Cytotoxicity against human HeLa cells assessed as growth inhibition after 48 hrs by CCK-8 assay	[PMID: 22041063]
HeLa	IC₅₀	36 μM Compound: 2, DPT	Cytotoxicity against human HeLa cells after 48 hrs by MTT assay Cytotoxicity against human HeLa cells after 48 hrs by MTT assay	[PMID: 21733601]
HeLa	IC₅₀	6.01 μM Compound: 9, DPT	Cytotoxicity against human HeLa cells after 48 hrs by CCK-8 assay Cytotoxicity against human HeLa cells after 48 hrs by CCK-8 assay	[PMID: 22244588]
HepG2	IC₅₀	14.5 μg/mL Compound: 10	Antiproliferative activity against human HepG2 cells assessed as inhibition of cell viability by MTT assay Antiproliferative activity against human HepG2 cells assessed as inhibition of cell viability by MTT assay	[PMID: 32223924]
HL-60	IC₅₀	0.47 μM Compound: 9, DPT	Cytotoxicity against human HL60 cells after 48 hrs by CCK-8 assay Cytotoxicity against human HL60 cells after 48 hrs by CCK-8 assay	[PMID: 22244588]
HL-60	IC₅₀	0.47 μM Compound: 8, DPT	Cytotoxicity against human HL60 cells assessed as growth inhibition after 48 hrs by CCK-8 assay Cytotoxicity against human HL60 cells assessed as growth inhibition after 48 hrs by CCK-8 assay	[PMID: 22041063]
HT-29	IC₅₀	16.6 nM Compound: DPT	Antiproliferative activity against human HT-29 cells measured after 72 hrs by MTT assay Antiproliferative activity against human HT-29 cells measured after 72 hrs by MTT assay	[PMID: 36471625]
K562	IC₅₀	16 nM Compound: DPT	Antiproliferative activity against human K562 cells measured after 72 hrs by MTT assay Antiproliferative activity against human K562 cells measured after 72 hrs by MTT assay	[PMID: 36471625]
KB	IC₅₀	0.003 μM Compound: Dppt	Cytotoxicity against human KB cells assessed as inhibition of cell proliferation after 72 hrs by MTS assay Cytotoxicity against human KB cells assessed as inhibition of cell proliferation after 72 hrs by MTS assay	[PMID: 22429510]
KB	IC₅₀	0.0089 μM Compound: 7	Cytotoxicity against human KB cells after 72 hrs by MTT assay Cytotoxicity against human KB cells after 72 hrs by MTT assay	[PMID: 21570846]
KM-20L2	GI₅₀	0.0014 μg/mL Compound: 1	Growth inhibition of human KM20L2 cells measured after 48 hrs by sulforhodamine B assay Growth inhibition of human KM20L2 cells measured after 48 hrs by sulforhodamine B assay	[PMID: 26938998]
KM-20L2	ED₅₀	0.0028 μg/mL Compound: 2	Anticancer activity against human KM20L2 cells after 48 hrs by SRB assay Anticancer activity against human KM20L2 cells after 48 hrs by SRB assay	[PMID: 14987061]
MCF7	ED₅₀	0.0021 μg/mL Compound: 2	Anticancer activity against human MCF7 cells after 48 hrs by SRB assay Anticancer activity against human MCF7 cells after 48 hrs by SRB assay	[PMID: 14987061]
MCF7	GI₅₀	0.0027 μg/mL Compound: 1	Growth inhibition of human MCF7 cells measured after 48 hrs by sulforhodamine B assay Growth inhibition of human MCF7 cells measured after 48 hrs by sulforhodamine B assay	[PMID: 26938998]
MCF7	IC₅₀	6 nM Compound: DPT	Antiproliferative activity against human MCF7 cells measured after 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells measured after 72 hrs by MTT assay	[PMID: 36471625]
MDA-MB-231	IC₅₀	0.07 μg/mL Compound: 10	Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell viability by MTT assay Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell viability by MTT assay	[PMID: 32223924]
NCI-H460	GI₅₀	0.0018 μg/mL Compound: 1	Growth inhibition of human NCI-H460 cells measured after 48 hrs by sulforhodamine B assay Growth inhibition of human NCI-H460 cells measured after 48 hrs by sulforhodamine B assay	[PMID: 26938998]
NCI-H460	ED₅₀	0.0027 μg/mL Compound: 2	Anticancer activity against human NCI-H460 cells after 48 hrs by SRB assay Anticancer activity against human NCI-H460 cells after 48 hrs by SRB assay	[PMID: 14987061]
P388	ED₅₀	0.0023 μg/mL Compound: 2	Anticancer activity against mouse P388 cells after 48 hrs Anticancer activity against mouse P388 cells after 48 hrs	[PMID: 14987061]
P388	ED₅₀	0.029 μg/mL Compound: 1	Growth inhibition of mouse P388 cells measured after 48 hrs by sulforhodamine B assay Growth inhibition of mouse P388 cells measured after 48 hrs by sulforhodamine B assay	[PMID: 26938998]
PC-3	IC₅₀	0.018 μM Compound: 8	Antiproliferative activity against human PC3 cells after 72 hrs by MTT assay Antiproliferative activity against human PC3 cells after 72 hrs by MTT assay	[PMID: 27214307]
SF-268	GI₅₀	0.00056 μg/mL Compound: 1	Growth inhibition of human SF268 cells measured after 48 hrs by sulforhodamine B assay Growth inhibition of human SF268 cells measured after 48 hrs by sulforhodamine B assay	[PMID: 26938998]
SF-268	ED₅₀	0.0033 μg/mL Compound: 2	Anticancer activity against human SF268 cells after 48 hrs by SRB assay Anticancer activity against human SF268 cells after 48 hrs by SRB assay	[PMID: 14987061]
SiHa	IC₅₀	1.98 μM Compound: 9, DPT	Cytotoxicity against human SiHa cells after 48 hrs by MTT assay Cytotoxicity against human SiHa cells after 48 hrs by MTT assay	[PMID: 22244588]
SiHa	IC₅₀	10.2 μM Compound: 2, DPT	Cytotoxicity against human SiHa cells after 48 hrs by MTT assay Cytotoxicity against human SiHa cells after 48 hrs by MTT assay	[PMID: 21733601]
SiHa	IC₅₀	6.01 μM Compound: 8, DPT	Cytotoxicity against human SiHa cells assessed as growth inhibition after 48 hrs by MTT assay Cytotoxicity against human SiHa cells assessed as growth inhibition after 48 hrs by MTT assay	[PMID: 22041063]

In Vitro

Deoxypodophyllotoxin (25-75 nM; 6-48 hours) increases the percentage of early apoptotic cell population from 2.05 to 5.62 and 18.49% for 24 h and 48 h, respectively^[1].
Deoxypodophyllotoxin (25-75 nM; 6-48 hours) treats SGC-7901 cells arrested in G2/M phase in time- and dose- dependent manners^[1].
Deoxypodophyllotoxin (25-75 nM; 6-48 hours) results in a remarkably time- and dose-dependent decrease in Cdc2 and Cdc25C expression levels and increases cyclin B1 within 6h, decreases PARP, Bcl-2 and caspase-3 activity^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Apoptosis Analysis^[1]

Cell Line:	SGC-7901 cells
Concentration:	25, 50, 75 nM
Incubation Time:	6, 12, 24, 48 hours
Result:	Induced apoptosis in SGC-7901 Cells.

Cell Cycle Analysis^[1]

Cell Line:	SGC-7901 cells
Concentration:	25, 50, 75 nM
Incubation Time:	6, 12, 24, 48 hours
Result:	Induced G2/M cell cycle arrest in SGC-7901 Cells

Western Blot Analysis^[1]

Cell Line:	SGC-7901 cells
Concentration:	25, 50, 75 nM
Incubation Time:	6, 12, 24, 48 hours
Result:	Altered the expression of cyclin B1, Cdc2,Cdc25C, p-PARP, Bcl-2 and p-caspase-3 proteins.

In Vivo

Deoxypodophyllotoxin (intravenously injected; 5, 10, and 20 mg/kg; 3 times a week; 28 days) suppresses the tumors in a dose-dependent manner, the growth of tumors is inhibited by 22.19%, 47.91% and 50.93% with DPT at 5, 10 and 20 mg/kg, respectively^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Xenograft model of gastric cancer in nude mice with SGC-7901 cells^[1]
Dosage:	5, 10, and 20 mg/kg
Administration:	Intravenously injected; 5, 10, and 20 mg/kg; 3 times a week; 28 days
Result:	Inhibited the growth of gastric cancer tumors.

Molecular Weight

398.41

Formula

C₂₂H₂₂O₇

CAS No.

19186-35-7

Appearance

Solid

Color

White to off-white

SMILES

O=C1[C@]2([H])[C@H](C3=CC(OC)=C(OC)C(OC)=C3)C4=CC(OCO5)=C5C=C4C[C@@]2([H])CO1

Structure Classification

Initial Source

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL (251.00 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	2.5100 mL	12.5499 mL	25.0998 mL
5 mM	0.5020 mL	2.5100 mL	5.0200 mL
10 mM	0.2510 mL	1.2550 mL	2.5100 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (6.27 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (6.27 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (6.27 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: 99.87%

Select Batch:

Data Sheet (284 KB) SDS (392 KB)

COA (258 KB) HNMR (263 KB) LCMS (94 KB)

Handling Instructions (2659 KB)

References

[1]. Wang YR, et al. Deoxypodophyllotoxin induces G2/M cell cycle arrest and apoptosis in SGC-7901 cells and inhibits tumor growth in vivo. Molecules. 2015 Jan 20;20(1):1661-75. [Content Brief]

[2]. Kim SH, et al. Deoxypodophyllotoxin induces cytoprotective autophagy against apoptosis via inhibition of PI3K/AKT/mTOR pathway in osteosarcoma U2OS cells. Pharmacol Rep. 2017 Oct;69(5):878-884. [Content Brief]

[3]. Xu P, et al. Pharmacological effect of deoxypodophyllotoxin: a medicinal agent of plant origin, on mammalian neurons. Neurotoxicology. 2010 Dec;31(6):680-6. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	2.5100 mL	12.5499 mL	25.0998 mL	62.7494 mL
	5 mM	0.5020 mL	2.5100 mL	5.0200 mL	12.5499 mL
	10 mM	0.2510 mL	1.2550 mL	2.5100 mL	6.2749 mL
	15 mM	0.1673 mL	0.8367 mL	1.6733 mL	4.1833 mL
	20 mM	0.1255 mL	0.6275 mL	1.2550 mL	3.1375 mL
	25 mM	0.1004 mL	0.5020 mL	1.0040 mL	2.5100 mL
	30 mM	0.0837 mL	0.4183 mL	0.8367 mL	2.0916 mL
	40 mM	0.0627 mL	0.3137 mL	0.6275 mL	1.5687 mL
	50 mM	0.0502 mL	0.2510 mL	0.5020 mL	1.2550 mL
	60 mM	0.0418 mL	0.2092 mL	0.4183 mL	1.0458 mL
	80 mM	0.0314 mL	0.1569 mL	0.3137 mL	0.7844 mL
	100 mM	0.0251 mL	0.1255 mL	0.2510 mL	0.6275 mL